

Biocon Biologics, Viatris launch oncology biosimilar Abevmy in Canada

19 May 2022 | News

The two formats are available in 100 mg/4 mL single-use vial and 400 mg/16 mL single-use vial



Biocon Biologics and Viatris announced that Abevmy (bBevacizumab) is now available in Canada. Abevmy, co-developed by Biocon Biologics and Viatris, is a biosimilar to Roche's Avastin (Bevacizumab) and has been approved by Health Canada across four oncology indications.

Abevmy follows the launch of our two oncology biosimilars in Canada, Ogviri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020. In addition to the therapeutic area of oncology, Viatris Canada launched Hulio (bAdalimumab) in February 2021 for chronic inflammatory conditions.

Abevmy is authorised for use in the following indications:

- Metastatic Colorectal Cancer (mCRC)
- Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary
- Peritoneal Cancer
- Malignant Glioma (WHO Grade IV) - Glioblastoma

The two formats approved and now available in Canada are 100 mg/4 mL single-use vial and 400 mg/16 mL single-use vial.